Results 111 to 120 of about 15,767 (251)

The effect of time on associations between historical redlining and breast cancer survival

Cancer, Volume 132, Issue 4, 15 February 2026.
Abstract Background Historical redlining, a 1930s residential segregation policy, has been associated with shorter breast cancer survival. It is unknown whether this disparity has changed over time, given the time since redlining increases and subsequent breast cancer advances have occurred.
Sarah M. Lima, Tia M. Palermo, Lili Tian, Furrina F. Lee, Tabassum Z. Insaf, Helen C. S. Meier, Henry Louis Taylor Jr, Deborah O. Erwin, Heather M. Ochs‐Balcom   +8 more
wiley   +1 more source

Effects of DTX3L on the cell proliferation, adhesion, and drug resistance of multiple myeloma cells

Tumor Biology, 2017
Cell adhesion–mediated drug resistance is an important factor that influences the effects of chemotherapy in multiple myeloma. DTX3L, a ubiquitin ligase, plays a key role in cell-cycle-related process.
Yaodong Shen, Yuxiang Sun, Linlin Zhang, Hong Liu   +3 more
doaj   +1 more source

Enzymic Adenosine Diphosphate Ribosylation of Histone and Poly Adenosine Diphosphate Ribose Synthesis in Rat Liver Nuclei

Journal of Biological Chemistry, 1968
An enzyme associated with mammalian chromatin catalyzed the transfer of the adenosine diphosphate ribose moiety of nicotinamide adenine dinucleotide to histone with the simultaneous release of nicotinamide. A successive transfer of the ADP-ribose moiety resulted in the formation and elongation of a homopolymer with repeating ADP-ribose units ...
Y, Nishizuka, K, Ueda, T, Honjo, O, Hayaishi   +3 more
openaire   +2 more sources

PARP inhibitors elicit distinct transcriptional programs in homologous recombination competent castration‐resistant prostate cancer

Molecular Oncology, Volume 20, Issue 2, Page 369-388, February 2026.
PARP inhibitors are used to treat a small subset of prostate cancer patients. These studies reveal that PARP1 activity and expression are different between European American and African American prostate cancer tissue samples. Additionally, different PARP inhibitors cause unique and overlapping transcriptional changes, notably, p53 pathway upregulation.
Moriah L. Cunningham, Jasibel Vasquez‐Gonzalez, Samantha M. Barnada, Salome Tchotorlishvili, Latese Jones, Ryan Maguire, Genevieve Lewis, Kinza Rizwan, Jenny Deng, Salma Koachar, Drithi Patel, Hailey Shankle, Tessa Mulders, Namra Ajmal, Charalambos Solomides, Emad S. Alnemri, Teresa F. Alnemri, Ayesha A. Shafi, Leonard G. Gomella, Wm Kevin Kelly, Steven B. McMahon, Matthew J. Schiewer   +21 more
wiley   +1 more source

Management of HER2-Low Metastatic Breast Cancer: A Comprehensive Statement by an Expert Group from the Middle East and Africa Region [PDF]

Middle East Journal of Cancer
Approximately 50 to 67% of breast cancers (BCs), traditionally categorized as human epidermal growth factor receptor 2 (HER2)-negative, but demonstrating low HER2 expression, are now being defined as a new HER2-low subset or HER2-low category of BC.
Shaheenah Dawood, Mohsen Mokhtar, Ahmed Alwbari, Bernardo Rapoport, Ece Esin, Hassan Jaafar, Jamal Zekri, Narjiss Berrada, Ozgur Ozyilkan, Nagi El Saghir   +9 more
doaj   +1 more source

Drug hypersensitivity caused by alteration of the MHC-presented self-peptide repertoire [PDF]

, 2012
Idiosyncratic adverse drug reactions are unpredictable, dose independent and potentially life threatening; this makes them a major factor contributing to the cost and uncertainty of drug development. Clinical data suggest that many such reactions involve
A. Lucas, A. M. English, A. Sette, A. Wriston, B. J. Grant, B. Peters, C. A. F. de Oliveira, C. Oseroff, Cahalan, Chessman, Chung, D. A. Ostrov, D. F. Hunt, Day, E. Phillips, Faletto, Friesner, H. M. Grey, H. Mei, Harndahl, J. Jakoncic, J. Shabanowitz, J. Sidney, Ko, L. Shi, L. Yang, Lavergne, M. Harndahl, Mallal, Martin, Melroy, Phillips, Pichler, Rudolph, S. Buus, S. Lu, S. Mallal, S. Southwood, Shastri, Shimizu, Sidney, Sidney, Tenzer, Udeshi, Y. A. Pompeu, Yang, Yang, Yewdell   +47 more
core   +4 more sources

Interaction of Nucleosides and Related Compounds with Nucleic Acids as Indicated by the Change of Helix-Coil Transition Temperature [PDF]

, 1962
A series of compounds has been tested for effectiveness in lowering the melting temperature of poly A and of thymus DNA. The order of increasing activity was found to be: adonitol, methyl riboside (both negligible) < cyclohexanol < phenol, pyrimidine ...
Helmkamp, G. K., Sander, C., T'so, Paul O. P.   +2 more
core   +1 more source

The Concise Guide to PHARMACOLOGY 2015/16:Enzymes [PDF]

, 2015
The Concise Guide to PHARMACOLOGY 2015/16 provides concise overviews of the key properties of over 1750 human drug targets with their pharmacology, plus links to an open access knowledgebase of drug targets and their ligands (www.guidetopharmacology.org),
Aldrich, R, Alexander, SPH, Attali, B, Back, M, Barnes, NM, Bathgate, R, Beart, PM, Becirovic, E, Benson, HE, Biel, M, Birdsall, NJ, Boison, D, Brauner-Osborne, H, Broeer, S, Bryant, C, Burnstock, G, Burris, T, Cain, D, Calo, G, Chan, SL, Chandy, KG, Chiang, N, Christakos, S, Christopoulos, A, Chun, JJ, Chung, J-J, Clapham, DE, Connor, MA, Coons, L, Cox, HM, Dautzenberg, FM, Davies, JA, Dent, G, Douglas, SD, Dubocovich, ML, Edwards, DP, Fabbro, D, Faccenda, E, Farndale, R, Fong, TM, Forrest, D, Fowler, CJ, Fuller, P, Gainetdinov, RR, Gershengorn, MA, Goldin, A, Goldstein, SAN, Grimm, SL, Grissmer, S, Gundlach, AL, Hagenbuch, B, Hammond, JR, Hancox, JC, Hartig, S, Hauger, RL, Hay, DL, Hebert, T, Hollenberg, AN, Holliday, ND, Hoyer, D, Ijzerman, AP, Inui, KI, Ishii, S, Jacobson, KA, Jan, LY, Jarvis, GE, Jensen, R, Jetten, A, Jockers, R, Kaczmarek, LK, Kanai, Y, Kang, HS, Karnik, S, Kelly, E, Kerr, ID, Korach, KS, Lange, CA, Larhammar, D, Leeb-Lundberg, F, Leurs, R, Lolait, SJ, Macewan, D, Maguire, JJ, Marrion, N, May, JM, Mazella, J, McArdle, CA, McDonnell, DP, Michel, MC, Miller, LJ, Mitolo, V, Monie, T, Monk, PN, Mouillac, B, Murphy, PM, Nahon, J-L, Nerbonne, J, Nichols, CG, Norel, X, Oakley, R, Offermanns, S, Palmer, LG, Panaro, MA, Pawson, AJ, Perez-Reyes, E, Pertwee, RG, Peters, JA, Pike, JW, Pin, JP, Pintor, S, Plant, LD, Poyner, DR, Prossnitz, ER, Pyne, S, Ren, D, Richer, JK, Rondard, P, Ross, RA, Sackin, H, Safi, R, Sanguinetti, MC, Sartorius, CA, Segaloff, DL, Sharman, JL, Sladek, FM, Southan, C, Stewart, G, Stoddart, LA, Striessnig, J, Summers, RJ, Takeda, Y, Tetel, M, Toll, L, Trimmer, JS, Tsai, M-J, Tsai, SY, Tucker, S, Usdin, TB, Vilargada, J-P, Vore, M, Ward, DT, Waxman, SG, Webb, P, Wei, AD, Weigel, N, Willars, GB, Winrow, C, Wong, SS, Wulff, H, Ye, RD, Young, M, Zajac, J-M   +151 more
core   +4 more sources

Neoadjuvant fuzuloparib combined with abiraterone for localized high-risk prostate cancer (FAST-PC): A single-arm phase 2 study

Cell Reports Medicine
Summary: Preclinical studies suggest synergistic effects between androgen receptor inhibitors and poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors.
Tingwei Zhang, Beihe Wang, Yu Wei, Hualei Gan, Bangwei Fang, Xiaomeng Li, Junlong Wu, Xiaojie Bian, Jianfei Wang, Stephen J. Freedland, Shenglin Huang, Dingwei Ye, Yao Zhu   +12 more
doaj   +1 more source

Niraparib in ovarian cancer. results to date and clinical potential [PDF]

, 2017
Ovarian cancer is the first cause of death from gynaecological malignancy. Germline mutation in BRCA1 and 2, two genes involved in the mechanisms of reparation of DNA damage, are showed to be related with the incidence of breast and ovarian cancer, both ...
Benedetti Panici, Pierluigi, Caruso, Davide, Papa, Anselmo, Tomao, Federica, Tomao, Silverio, Vici, Patrizia   +5 more
core   +1 more source